摘要
抗结核药物性肝损伤(ADLI)是抗结核治疗中严重的不良反应之一,迄今尚无治疗ADLI的特效药物。近年来,ADLI发生率日益增高,极大地加重了患者及社会的医疗负担。随着宏基因测序等技术的发展,肠道菌群与ADLI的相关研究也逐渐增多。本文就肠道菌群与ADLI的相关性研究进行综述。
Antituberculous drug-induced liver injury(ADLI)is one of the serious adverse reactions of anti-tuberculosis therapy.There is no specific drug to treat ADLI.In recent years,the increasing incidence of ADLI has greatly increased the medical burden of patients and society.With the development of macrogene sequencing and other technologies,the researches on intestinal flora and ADLI are increasing.Under such background,this paper aims to review the relationship between intestinal microflora and ADLI.
作者
梁思敏
贾斌
LIANG Simin;JIA Bin(Department of Respiratory,the First Affiliated Hospital of Xinjiang Medical University,Urumqi,Xinjiang 830011,China)
出处
《医药前沿》
2022年第31期40-42,46,共4页
Journal of Frontiers of Medicine
基金
基于肠道微生态探索黄酒功能因子的健康养生作用(2020B33002)
黄酒多酚联合粪菌移植在阿霉素诱导的线粒体分裂/融合异常中的作用和分子机制研究(82174204)。
关键词
综述
肠-肝轴
肠道菌群
抗结核药物
肝损伤
Review
Gut-Liver Axis
Intestinal Microflora
Antituberculous Drug
Liver Injury
